03 Oct

BullFrog AI (BFRG): Turning Unstructured Data into Actionable Insights

By Chris AbbottHealthcare,
In the current AI boom, one area that has struggled is companies attempting to build sustainable businesses around AI itself. A few companies have figured out how to monetize AI in ways investors view as durable, while the traditional picks-and-shovels businesses, such as NVDA, SNDK, IREN, CRWV, and others, have performed well. Broadly, however, many companies built using AI applications have struggled. So why are we spending time looking at BullFrog AI? We believe it is one of the rare exceptions in the AI space with a genuinely interesting business model. BFRG has built a platform designed to take unstructured…
Read More
11 Sep

Modular Medical: Everyone Loves a Ferrari, but More People Drive Honda Civic’s

By Chris AbbottHealthcare,
Diabetes is a significant challenge for the U.S. healthcare system. According to the 2024 Seagrove Diabetes Bluebook, roughly 25% of all healthcare spending in the U.S. goes toward diabetes management. Despite this, only about one-third of U.S. Type 1 diabetics use an insulin pump, and for Type 2 diabetics, that figure is just 10%. This indicates a large, untapped opportunity to expand pump usage, particularly in the Type 2 diabetes market, which has more patients but lower pump adoption. The insulin pump market is currently dominated by three key players: Medtronic, Tandem, and Insulet, each holding approximately one-third of the market.…
Read More
29 Jun

Historically Discounted RTI Surgical Transitioning To Pure Play Spine Competitor With Significant Upside

By Chris AbbottHealthcare, ,
RTI Surgical (RTIX, now SRGA) is on the precipice of a transformation due to the divestiture of its OEM business to Montagu Private Equity. This divestiture can be viewed as the culmination of several years’ work to simplify the business by its relatively new CEO, Camille Farhat, as well as the beginning of an exciting transition to a pure-play high margin growing spine company and hopefully, the accompanying valuation. At 1035 Capital, we have followed SRGA since Farhat was hired as CEO and waited for this kind of catalyst to make SRGA a really exciting opportunity. Read more on Seeking…
Read More
28 Jan

OptimizeRx Corp: Optimize Your Portfolio With This Under The Radar Health Tech Company

By Chris AbbottHealthcare,
OptimizeRx Corporation (OPRX) is a healthcare IT company focused on improving messaging between manufacturers, patients, payors and doctors. OPRX's first major product, financial messaging, allowed it to penetrate the healthcare communications space. Since then, the company has added 3 additional products which are moving OPRX up the value chain toward enterprise deals where it will provide a variety of messaging solutions instead of one-off project work. Read more on Seeking Alpha...
Read More
31 Oct

Teligent: 100% Upside Based On Revised SOTP With Several Near-Term Catalysts

By Chris AbbottHealthcare,
1035 Capital recently wrote an article on TLGT highlighting the underappreciated value of this turnaround generic manufacturer. As we predicted, there has been significant volatility in the share price. Since publication on Aug 8th, the price spiked up to ~$1.10 and has recently slid all the way back to the $0.60 range. In our previous article, 1035 Capital provided background information on TLGT and we argued the company is worth $2-2.75/share. Recent announcements within the past month have provided us a better understanding of the value of the company’s assets and based on this new information, we believe the sum of TLGT’s…
Read More
14 Aug

Supernus Pharmaceuticals: Anti-CGRPs Are Causing Migraines For This Biotech But Investors Are Too Pessimistic Creating A Compelling Opportunity

By Chris AbbottHealthcare
Supernus Pharmaceuticals (SUPN) was founded in 2005 and was previously a subsidiary of Shire PLC (SHPG). SUPN and its management team have developed and commercialized the central nervous system ("CNS") products for more than 25 years. The company's two commercial products are Oxtellar XR® and Trokendi XR® both originally for the treatment of epilepsy. SUPN drugs are extended-release versions of earlier immediate-release branded products. SUPN found that by using extended-release formulations, these two molecules could achieve smoother blood saturation levels resulting in patients with fewer negative side effects and better disease management. In August 2016, SUPN expanded the label for Trokendi by gaining…
Read More
08 Apr

Teligent: Micro-Cap Specialty Generic

By Chris AbbottHealthcare, ,
Teligent (NASDAQ: TLGT) currently produces over 70 topical and injectable products across the US and Canada. TLGT was once an exciting high growth generic manufacturer but stumbled in the last few years as they invested to expand their manufacturing capabilities. The company embarked on a strategy to focus on TICO, topical, injectable, complex and ophthalmic generics in 2014 under the premise that there are less competition and greater pricing stability in these niche portions of the generic market. Given the small size of TLGT, these niche markets still provide plenty of room for growth. While the strategy to shift the…
Read More